EGFR and neoplasm: Recently, many publications have explored the association of tumour mutations, especially epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), Kirsten rat sarcoma viral oncogene homolog (KRAS), and ROS1 mutations, with 18 F-FDG radiomics features for in vivo non-invasive diagnostic or prognostic purposes [3,4,5].